The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Julia Aijun Wang net worth and biography

Julia Wang Biography and Net Worth

CFO of BeiGene

Julia Wang joined BeiGene in June 2020 and currently serves as Chief Financial Officer. In this role, she will partner across the enterprise to optimize intrinsic value creation through greater financial discipline. Ms. Wang has extensive global finance experience across biotech, pharmaceutical, medical devices, diagnostic testing, and consumer products. She was most recently Senior Vice President, Global Business Finance, Corporate Finance and Corporate FP&A at Alexion Pharmaceuticals, and prior to that position she served in various leadership roles at Quest Diagnostics. Previously, Ms. Wang spent over five years at Johnson & Johnson leading finance at several operating companies, including Xian-Janssen Pharmaceutical, J&J’s pharmaceutical business in China. She received an MBA from Fuqua School of Business at Duke University and a B.A. in British Language and Literature from Shandong Normal University.

How do I contact Julia Aijun Wang?: The corporate mailing address for Ms. Wang and other BeiGene executives is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. BeiGene can also be reached via phone at (345) 949-4123 and via email at [email protected]. Learn More on Julia Aijun Wang's contact information.
Has Julia Aijun Wang been buying or selling shares of BeiGene?: Julia Aijun Wang has not been actively trading shares of BeiGene in the last ninety days. Most recently, Julia Aijun Wang sold 397 shares of the business's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $167.08, for a transaction totalling $66,330.76. Learn More on Julia Aijun Wang's trading history.
Who are BeiGene's active insiders?: BeiGene's insider roster includes Timothy Chen (Director), Donald Glazer (Director), Jane Huang (CMO), Chan Lee (SVP), Howard Liang (CFO), John Oyler (CEO), Corazon (Corsee) Sanders (Director), Julia Wang (CFO), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on BeiGene's active insiders.
Are insiders buying or selling shares of BeiGene?: During the last twelve months, insiders at the sold shares 16 times. They sold a total of 2,769,908 shares worth more than $568,875,239.08. The most recent insider tranaction occured on April, 10th when CEO John Oyler sold 26,716 shares worth more than $3,977,745.24. Insiders at BeiGene own 7.4% of the company. Learn More about insider trades at BeiGene.
Information on this page was last updated on 4/10/2024.

Julia Aijun Wang Insider Trading History at BeiGene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/29/2024	Sell	397	$167.08	$66,330.76
7/3/2023	Sell	472	$179.55	$84,747.60
6/23/2023	Sell	840	$182.85	$153,594.00
7/1/2022	Sell	295	$158.50	$46,757.50
6/17/2022	Sell	161	$136.64	$21,999.04
7/1/2021	Sell	308	$349.06	$107,510.48

Julia Aijun Wang Buying and Selling Activity at BeiGene

BeiGene Company Overview

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Today's Range

Now: $131.96

$131.40

$136.00

50 Day Range

MA: $155.65

$131.86

$179.69

2 Week Range

Now: $131.96

$131.28

$266.67

Volume

125,955 shs

Average Volume

259,587 shs

Market Capitalization

$12.62 billion

P/E Ratio

N/A

Dividend Yield